Skip to main content

Table 1 Study population characteristics

From: HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

Feature

n

Sex, male (%)

20/25 (80%)

25

HIV-1 subtype B (%)

25/25 (100%)

25

Plasma HIV-1 RNA, log10 copies/mL [mean (SD)]

4.17 (1.11)

22

CD4 + T-Cell count, cells/mm3 [mean (SD)]

328.5 (217.07)

12

RAL exposure time, months [mean (SD)]

22.33 (20.38)

15

Time on ART, years [mean (SD)]

10.65 (5.7)

12

Total prior ART regimens [mean (SD)]

5.31 (3.13)

16

Optimized backbone regimen (%)

17

 NRTIs

5/17 (29.41%)

17

 NRTIs + PI

5/17 (29.41%)

17

 NNRTIs + PI

3/17 (17.65%)

17

 NRTIs + NNRTIs

1/17 (5.88%)

17

 Othera

3/17 (17.65%)

17

  1. SD standard deviation, NRTIs nucleoside reverse transcriptase inhibitors, PI protease inhibitor, NNRTIs non-nucleoside reverse transcriptase inhibitors, ART antiretroviral therapy
  2. aRegimens including enfuvirtide. N = 25